It's all in the name, or is it? The impact of labelling on health state values

Many descriptions of health used in vignettes and condition-specific measures refer to the medical condition. This paper assesses the impact of referring to the medical condition in the descriptions of health states valued by members of the general population. A sample of 241 members of the UK general population each valued 8 health states using time trade-off. All respondents valued essentially the same health states, but for each respondent the descriptions featured either an irritable bowel syndrome label, a cancer label or no label. Regression techniques were used to estimate the impact of each label and experience of the condition on health state values. We find that the inclusion of a cancer label in health state descriptions affects health state values and that the impact is dependent upon the severity of the state. A condition label can affect health state values, but this is dependent upon the specific condition and severity. It is recommended to avoid condition labels in health state descriptions (where possible) to ensure that values are not affected by prior knowledge or preconception of the condition that may distort the health state being valued

The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results

Background: Previous methods of empirical mapping involve using regressions on patient or general population self-report data from datasets involving 2 or more instruments. This approach relies on overlap in the descriptive systems of the measures, but key dimensions may not be present in both measures. Furthermore, this assumes it is appropriate to use different instruments on the same population, which may not be the case for all patient groups. The aim of the study described here is to develop a new method of mapping using general population preferences for hypothetical health states defined by the descriptive systems of different measures. This paper presents a description of the methods used in the study and reports on the results of the valuation study including details about the respondents, feasibility and quality (e.g. response rate, completion and consistency) and descriptive results on VAS and ranking data. The use of these results to estimate mapping functions between instruments will be presented in a companion paper. Methods: The study used interviewer administered versions of ranking and VAS techniques to value 13 health states defined by each of 6 instruments: EQ-5D (generic), SF-6D (generic), HUI2 (generic for children), AQL-5D (asthma specific), OPUS (social care specific), ICECAP (capabilities). Each interview involved 3 ranking and visual analogue scale (VAS) tasks with states from 3 different instruments where each task involves the simultaneous valuation of multiple instruments. The study includes 13 health and well-being states for each instrument (16 for EQ-5D) that reflect a range of health state values according to the published health state values for each instrument and each health state is valued approximately 75-100 times. Results: The sample consists of 499 members of the UK general population with a reasonable spread of background characteristics (response rate=55%). The study achieved a completion rate of 99% for all states included in the rank and rating tasks and 94.8% of respondents have complete VAS responses and 97.2% have complete rank responses. Interviewers reported that it is doubtful for 4.1% of respondents that they understood the tasks, and 29.3% of respondents stated that they found the tasks difficult. The results suggest important differences in the range of mean VAS and mean rank values per state across instruments; for example, mean VAS values for the worst state vary across instruments from 0.075 to 0.324. Respondents are able to change the ordering of states between the rank and VAS tasks and 12.0% of respondents have one or more differences in their rank and VAS orderings for every task. Conclusions: This study has demonstrated the feasibility of simultaneously valuing health states from different preference-based instruments. The preliminary analysis of the results presented here provides the basis for a new method of mapping between measures based on general population preferences

The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results

Background: Previous methods of empirical mapping involve using regressions on patient or general population self-report data from datasets involving two or more instruments. This approach relies on overlap in the descriptive systems of the measures, but key dimensions may not be present in both measures. Furthermore this assumes it is appropriate to use different instruments on the same population, which may not be the case for all patient groups. The aim of the study described here is to develop a new method of mapping using general population preferences for hypothetical health states defined by the descriptive systems of different measures. This paper presents a description of the methods used in the study and reports on the results of the valuation study including details about the respondents, feasibility and quality (e.g. response rate, completion and consistency) and descriptive results on VAS and ranking data. The use of these results to estimate mapping functions between instruments will be presented in a companion paper. Methods: The study used interviewer administered versions of ranking and VAS techniques to value 13 health states defined by each of 6 instruments: EQ-5D (generic), SF-6D (generic), HUI2 (generic for children), AQL-5D (asthma specific), OPUS (social care specific), ICECAP (capabilities). Each interview involved 3 ranking and visual analogue scale (VAS) tasks with states from 3 different instruments where each task involves the simultaneous valuation of multiple instruments. The study includes 13 health and well-being states for each instrument (16 for EQ-5D) that reflect a range of health state values according to the published health state values for each instrument and each health state is valued approximately 75-100 times. Results: The sample consists of 499 members of the UK general population with a reasonable spread of background characteristics (response rate=55%). The study achieved a completion rate of 99% for all states included in the rank and rating tasks and 94.8% of respondents have complete VAS responses and 97.2% have complete rank responses. Interviewers reported that it is doubtful for 4.1% of respondents that they understood the tasks, and 29.3% of respondents stated that they found the tasks difficult. The results suggest important differences in the range of mean VAS and mean rank values per state across instruments, for example mean VAS values for the worst state vary across instruments from 0.075 to 0.324. Respondents are able to change the ordering of states between the rank and VAS tasks and 12.0% of respondents have one or more differences in their rank and VAS orderings for every task. Conclusions: This study has demonstrated the feasibility of simultaneously valuing health states from different preference-based instruments. The preliminary analysis of the results presented here provides the basis for a new method of mapping between measures based on general population preferences.preference-based measures of health; quality of life; mapping; visual analogue scale; ranking

It's all in the name, or is it? The impact of labelling on health state values

Many descriptions of health used in vignettes and condition-specific measures refer to the medical condition. This paper assesses the impact of referring to the medical condition in the descriptions of health states valued by members of the general population. A sample of 241 members of the UK general population each valued 8 health states using time trade-off. All respondents valued essentially the same health states, but for each respondent the descriptions featured either an irritable bowel syndrome label, a cancer label or no label. Regression techniques were used to estimate the impact of each label and experience of the condition on health state values. We find that the inclusion of a cancer label in health state descriptions affects health state values and that the impact is dependent upon the severity of the state. A condition label can affect health state values, but this is dependent upon the specific condition and severity. It is recommended to avoid condition labels in health state descriptions (where possible) to ensure that values are not affected by prior knowledge or preconception of the condition that may distort the health state being valued

Cytochrome P450 CYP1B1 interacts with 8-<i>methoxypsoralen</i> (8-MOP) and influences psoralen-Ultraviolet A (PUVA) sensitivity

Background: There are unpredictable inter-individual differences in sensitivity to psoralen-UVA (PUVA) photochemotherapy, used to treat skin diseases including psoriasis. Psoralens are metabolised by cytochrome P450 enzymes (P450), and we hypothesised that variability in cutaneous P450 expression may influence PUVA sensitivity. We previously showed that P450 CYP1B1 was abundantly expressed in human skin and regulated by PUVA, and described marked inter-individual differences in cutaneous CYP1B1 expression.Objectives: We investigated whether CYP1B1 made a significant contribution to 8-methoxypsoralen (8-MOP) metabolism, and whether individuality in CYP1B1 activity influenced PUVA sensitivity.Methods: We used E. coli membranes co-expressing various P450s and cytochrome P450 reductase (CPR) to study 8-MOP metabolism and cytotoxicity assays in CYP1B1-expressing mammalian cells to assess PUVA sensitivity.Results: We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism. As CYP1B1 is the most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the CYP1B1 substrates 7-ethoxyresorufin and 17-b-estradiol showed concentration-dependent inhibition by 8-MOP and (iii) inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype. The influence of CYP1B1 on PUVA cytotoxicity was further investigated in a Chinese hamster ovary cell line, stably expressing CYP1B1 and CPR, which was more sensitive to PUVA than control cells, suggesting that CYP1B1 metabolises 8-MOP to a more phototoxicmetabolite(s).Conclusion: Our data therefore suggest that CYP1B1 significantly contributes to cutaneous 8-MOP metabolism, and that individuality in CYP1B1 expression may influence PUVA sensitivity